GnRH agonists are the established treatment of precocious puberty caused by premature stimulation of gonadotropin secretion. It has been reported that after an initial stimulation ("flareup") they reduce LH secretion by desensitization of pituitary GnRH receptors. Little has been published about the use of GnRH antagonists such as cetrorelix to control the onset of puberty and whether they are potentially advantageous compared with GnRH agonists. We conducted two multigroup experiments (12 and 10 d, respectively) treating prepubertal/peripubertal female rats with either the GnRH agonist triptorelin or buserelin and compared them with rats treated with the GnRH antagonist cetrorelix and controls to assess the effects on pubertal progress and serum hormones. In the second experiment, the effects of buserelin and cetrorelix on gene expression of the GnRH receptor, LH-␤, FSH-␤, and the alpha subunit genes in the pituitary were also investigated. Cetrorelix, triptorelin, and buserelin retarded the onset of puberty as determined by delayed vaginal opening, lower ovarian weights, and lower serum estradiol levels. However, although LH and FSH levels were stimulated by both agonists, they were inhibited by cetrorelix. In the cetrorelix versus buserelin experiment, pituitary gene expression of the GnRH receptor and LH-␤ subunit were significantly lower in cetrorelix treated rats compared with controls whereas buserelin had little effect. Expression of FSH-␤ and alpha subunit were stimulated by buserelin but not by cetrorelix. Even though all three of these GnRH analogues inhibited gonadal development and delayed the onset of puberty, the GnRH agonists had stimulating and inhibiting effects on the pituitary-gonadal axis whereas cetrorelix exerted only inhibiting effects. We conclude from this female rat model that cetrorelix may offer advantages for a more controlled medical treatment of precocious puberty compared with GnRH agonist treatment. Onset of puberty is dependent on pulsatile release of hypothalamic GnRH from GnRH neurons (1). Premature release of GnRH causes central precocious puberty. GnRH agonists such as TRIP and BUS are the established treatment of central precocious puberty (2-4). Treatment with GnRH agonists causes an initial stimulation of the LH secretion ("flare-up"), which is followed by a low prepubertal LH secretion due to desensitization and/or down-regulation of pituitary GnRH receptors (4, 5). This method of treatment, however, is not without risks and side effects. Regular injections of these long-acting GnRH agonists are necessary to avoid a reactivation of the gonadotropin and gonadal steroid hormone secretion that occurs soon after treatment is discontinued (2).
GnRH agonists are the established treatment of precocious puberty caused by premature stimulation of gonadotropin secretion. It has been reported that after an initial stimulation ("flareup") they reduce LH secretion by desensitization of pituitary GnRH receptors. Little has been published about the use of GnRH antagonists such as cetrorelix to control the onset of puberty and whether they are potentially advantageous compared with GnRH agonists. We conducted two multigroup experiments (12 and 10 d, respectively) treating prepubertal/peripubertal female rats with either the GnRH agonist triptorelin or buserelin and compared them with rats treated with the GnRH antagonist cetrorelix and controls to assess the effects on pubertal progress and serum hormones. In the second experiment, the effects of buserelin and cetrorelix on gene expression of the GnRH receptor, LH-␤, FSH-␤, and the alpha subunit genes in the pituitary were also investigated. Cetrorelix, triptorelin, and buserelin retarded the onset of puberty as determined by delayed vaginal opening, lower ovarian weights, and lower serum estradiol levels. However, although LH and FSH levels were stimulated by both agonists, they were inhibited by cetrorelix. In the cetrorelix versus buserelin experiment, pituitary gene expression of the GnRH receptor and LH-␤ subunit were significantly lower in cetrorelix treated rats compared with controls whereas buserelin had little effect. Expression of FSH-␤ and alpha subunit were stimulated by buserelin but not by cetrorelix. Even though all three of these GnRH analogues inhibited gonadal development and delayed the onset of puberty, the GnRH agonists had stimulating and inhibiting effects on the pituitary-gonadal axis whereas cetrorelix exerted only inhibiting effects. We conclude from this female rat model that cetrorelix may offer advantages for a more controlled medical treatment of precocious puberty compared with GnRH agonist treatment. Onset of puberty is dependent on pulsatile release of hypothalamic GnRH from GnRH neurons (1) . Premature release of GnRH causes central precocious puberty. GnRH agonists such as TRIP and BUS are the established treatment of central precocious puberty (2) (3) (4) . Treatment with GnRH agonists causes an initial stimulation of the LH secretion ("flare-up"), which is followed by a low prepubertal LH secretion due to desensitization and/or down-regulation of pituitary GnRH receptors (4, 5) . This method of treatment, however, is not without risks and side effects. Regular injections of these long-acting GnRH agonists are necessary to avoid a reactivation of the gonadotropin and gonadal steroid hormone secretion that occurs soon after treatment is discontinued (2) .
Depending on the nature of the substitutions, synthetic GnRH analogues have either GnRH agonistic or GnRH antagonistic properties. The GnRH agonist TRIP (D-Trp 6 )-GnRH differs from the native peptide in position 6, the GnRH agonist BUS (D-Ser(tBu) 6 -NHEt 10 )-GnRH differs in positions 6 and 10, whereas the GnRH antagonist CET acetate (Ac-DNal (2) 1 ,D-Phe(4Cl) 2 ,D-Pal 3 ,D-Cit 6 ,D-Ala 10 )-GnRH contains substitutions in positions 1,2, 3, 6, and 10 (6). CET is now in phase III clinical studies (7, 8) for suppression of gonadotropins and gonadal hormones in men and women and has been widely used for endocrine applications such as in vitro fertilization, influencing lipoprotein subclasses, and treatment of prostate cancer and benign prostate hyperplasia (7, 9 -13) . CET has a strong inhibitory action on hormone release and has a low frequency of side effects compared with other antagonists for which anaphylactoid reactions due to histamine release and immunosuppressive effects have been reported (14 -16) .
Little has been reported about the use of CET in controlling the onset of puberty and whether this GnRH antagonist offers advantages for regulating pituitary hormone secretion compared with GnRH agonists. Therefore, we treated prepubertal female rats with CET or GnRH agonists to investigate the effects on pubertal development, serum hormone levels, and the gene expression of GnRH receptor, LH-␤, FSH-␤, and the alpha subunit in the pituitary.
METHODS
Animals, drugs, and serum hormones. Female Sprague Dawley rats were housed under standardized conditions (lights on 12 h from 0700 h to 1900 h, 25°C room temperature, 10 animals per cage). After randomization, in each cage were animals from all treatment groups. They had free access to water and were fed ad libitum. The doses of BUS, TRIP, and CET used have been shown to be effective in suppressing the gonadal hormones in previous experiments with rats (17, 18) . In both experiments drugs were diluted with NaCl 0.9% to a volume of 0.4 mL for each injection. All animals were monitored for changes of the external and internal genitalia. Vaginal opening marked the first estrous cycle and the beginning of puberty (in controls at postnatal d [33] [34] [35] [36] [37] [38] . The studies were approved by the local ethical committee for animal experiments at the University of Göttingen.
Experiment 1-CET versus TRIP: Animals were randomized in five groups, each consisting of 12-16 animals. From d 25 to d 36 (12 d) rats were intraperitoneally injected once per day at 1800 h with either 1 ϫ 0.4 mL NaCl 0.9% (placebo group), 1 ϫ 100 g or 1 ϫ 10 g CET (CET 100 or CET 10 group) or 1 ϫ 100 g or 1 ϫ 10 g TRIP (TRIP 100 or TRIP 10 group). Serum gonadotropins were measured at four different time points during treatment: 14 h after first injection; 24 h after third injection; 2 h after ninth injection; 14 h after last injection of drugs after decapitation in the morning. The first three blood samples were obtained by cannulation of the tail artery in slight ether narcosis and the fourth blood sample was collected from the trunk immediately after decapitation at d 37.
Experiment 2-CET versus BUS: Three groups consisting of 38 -41 animals per group were formed by randomization. From d 28 to d 37 (10 d) rats were intraperitoneally injected with either 2 ϫ 0.4 mL NaCl 0.9% daily at 0700 h (placebo group), 1 ϫ 100 g CET daily at 0700 h or 2 ϫ 30 g BUS daily at 0700 h and 1800 h. On d 37, rats of all three groups were decapitated 2 h after the last injection in the morning. Trunk blood was collected for measuring serum hormone levels and anterior pituitaries were rapidly removed and frozen on dry ice for mRNA studies.
Serum levels of LH , FSH, and estradiol levels were determined using established RIA methods. The antibodies were NIADDK rat-S7 (LH) and NIADDK rat-S11 (FSH); estradiol was measured by using a sensitive RIA (Diagnostic Systems Laboratories) with a lower detection limit of 6 pg/mL. Reference preparations were RP2 for both LH and FSH. For iodination, LH I-6 and FSH I-7 were used. To achieve maximum sensitivity 100 L serum was used for LH and FSH measurements. Each assay was performed with freshly prepared tracer that had been purified by fast protein liquid chromatographycolumn chromatography on Superdex 75 column (Amersham Pharmacia Biotech, Freiburg, Germany). In pilot experiments, fractions were tested for maximum sensitivity. Based on these data, an elution pattern of the chromatography with regard to the fraction containing the optimal tracer was established. Under these conditions sensitivity limits of 0.1 ng/mL (LH) and 0.4 ng/mL (FSH) were achieved. The intra-and interassay coefficients of variation from replicates of pooled samples from ovariectomized rats were 7.5% and 11.5% (LH) and 8.5% and 13.5% (FSH).
RNA-preparation and competitive RT-PCR. For generation of mutant RNA templates, composite primers were designed for each probe according to the method of Kephart (Promega Notes 68). These composite primers consist of the normal upstream or downstream primer sequence and a 15-bp sequence region located up to 100 nucleotides downstream in the RNA. An RT-PCR reaction was carried out with composite primer plus the respective sense or antisense primer and the resulting PCR products were cloned using the TOPO TA cloning kit (Invitrogen, Groningen, The Netherlands). After sequencing, the RNA was reverse transcribed with the Reverse Transcription System purchased from Promega. The isolation of total RNA from individual anterior pituitaries from animals in the second experiment was carried out with the RNeasy Total RNA Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. RNA concentrations were measured using the RiboGreen RNA quantitation reagent (Molecular Probes, Eugene, Oregon, U.S.A.). RT-PCR was conducted using SUPERSCRIPT for RT and SUPERMIX for PCR (both purchased from GIBCO-BRL, Eggenstein, Germany). The RT reaction was carried out with 150 ng total RNA. Before RT-PCR reaction, various amounts of mutant RNA were added to all reaction vials. The concentration of this cRNA was evaluated for each investigated gene by pilot titration experiments using 150 ng native RNA co-reverse transcribed and subsequently co-amplified with a serial dilution of the corresponding mutant cRNA as previously described (19) . For PCR reaction, 1-3 L cDNA and 25 pM primer were (20 -23) . The amplified PCR products were size-fractionated by electrophoresis in a 1.5% agarose gel in tris borate ethylene diamine tetracetic acid buffer and photographed after staining with ethidium bromide. Intensities of bands were evaluated with the Kodak DC 1D program.
Statistical evaluation and mathematical calculations. Unless otherwise stated, results are presented as mean Ϯ SEM. All data from the RIA and PCR analysis were statistically evaluated with one-way ANOVA followed by Dunnet's multiple t test using the Prism program (GraphPad Software, Inc. San Diego, CA, U.S.A.). In case of nonparametric distribution (serum gonadotropins), the statistical analysis was performed for each of the four time points separately on the significance level alpha ϭ 0.05 by using SAS 6.12 for Windows (SASInstitute, Cary, NC, U.S.A.). The exact Kruskal-Wallis test was used to compare multiple groups, whereas the exact MannWhitney test was used for comparisons in pairs. Differences were considered significant if p Ͻ 0.05.
RESULTS

Pubertal development, weights and serum hormones.
In both experiments all treated animals appeared to be healthy. The body weight gain and the weights at d 37 were similar for all groups of both studies. Pubertal development was inhibited by all three GnRH analogues, as determined by lower percentage of vaginal opening at pubertal age versus controls (Fig. 1,  a and b) . Efficiency of treatment was confirmed by the significant reduction of ovarian and uterine weights (Fig. 2, a-c) .
In the first experiment, after the first injection of CET 100 g, serum LH levels were significantly lower in CET-treated rats, whereas in TRIP-treated rats significantly higher LH levels were found. Suppression of LH by CET and stimulation of LH release by TRIP was observed during the entire treatment (Table 2a) . FSH levels were significantly lower under CET treatment and significantly higher after TRIP treatment compared with controls. FSH was more stimulated by TRIP 10 g/d than by TRIP 100 g/d (Table 2b ). In the second experiment, estradiol levels were significantly lower in both CET 
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and BUS treated rats (Fig. 3a) . Two hours after the last injection, serum LH levels were again suppressed by CET and stimulated by the agonist BUS (Fig. 3b) . FSH levels showed no significant change after CET treatment but were significantly higher after BUS treatment compared with controls (Fig. 3c) .
Gene expression of pituitary GnRH receptor and gonadotropin subunits. In experiment 2 (CET versus BUS), treatment with CET caused a significant reduction of the gene expression of the GnRH receptor in the pituitary. In contrast, in BUStreated rats the amount of GnRH receptor mRNA was slightly though not significantly higher than in the control group (Fig.  4) . Likewise, expression of gonadotropin subunit LH-␤ was lowered by CET whereas there was no effect in BUS-treated rats. FSH-␤ expression and alpha subunit expression were significantly stimulated by BUS, but CET treatment did not change the mRNA levels of either hormone subunits (Fig. 5) .
DISCUSSION
To our knowledge this is the first study in which the inhibitory effect of the GnRH antagonist CET on sexual maturation and on pituitary gene expression has been compared with the effects of the GnRH agonists TRIP and BUS. Our results demonstrate that each of the three GnRH analogues retards pubertal and gonadal development as indicated by a lower percentage of vaginal opening at pubertal age and, in particular, by lower ovarian weights and reduced estradiol levels. Even after shortening the treatment period, as in experiment 2, a profound inhibition of pubertal development was observed.
In CET-treated rats the serum LH and FSH levels were reduced, whereas during and after treatment with BUS or TRIP the serum LH and FSH levels were elevated. Nevertheless, retarded onset of pubertal development, lower ovarian and uterine weights, and lower estradiol levels were observed in the present study, implying that each GnRH analogue in effect inhibits the release of bioactive gonadotropins. The most likely explanation for this observation is that CET directly inhibits pituitary gonadotropin secretion whereas BUS and TRIP may cause intrinsic release of bioinactive gonadotropins. Supporting this idea are reports that in humans BUS releases bioinactive LH molecules into the circulation that are detected by RIA using polyclonal antibodies but not by immunoassays based on monoclonal antibodies (24, 25) . This hypothesis of bioinactive LH release caused by GnRH agonists is supported by the observation that sera from women under BUS treatment do not stimulate testosterone production in the mouse interstitial cell in vitro bioassay (26) . An alternative explanation for the elevated GnRH agonist-caused gonadotropin levels is that TRIP and BUS may cause a transient flare-up. To assess this phenomenon we collected blood samples at different time intervals (2 h, 14 h, and 24 h) after treatment. Our observations in this study contradicted the transient factor in the flare-up 471 explanation. We consistently found significantly elevated LH and FSH concentrations in samplings up to 24 h after treatment. Similarly, in another study a 12-d treatment of male rats with BUS led to reduced testes size and lower serum testosterone but unchanged LH levels 24 h after the last injection (27) . We postulate that after pretreatment with TRIP and BUS our RIA detected bioinactive rather than biologically active LH molecules, however further studies are needed to fully delineate the mechanisms of the GnRH analogues. The low estradiol levels found in this study may be due to the lowered gonadotropin levels (in the case of CET) or, as discussed above, could also be the consequence of release of bioinactive LH (in the cases of TRIP and BUS) and/or a direct action of GnRH-analogues in the ovary. In fact, GnRH and its agonists are known to directly affect steroid production and proliferation of human and rat granulosa cells via specific GnRH receptors (28 -30) . Furthermore, the human and rat ovary have been found to express GnRH, suggesting that the peptide may be involved in regulating the endocrine function of the ovary (31) (32) (33) . Recent data also indicate that CET reduces proliferation of granulosa cells more potently than BUS (34) . Thus the possibility cannot be ruled out that CET reduces estradiol secretion not only by inhibiting LH release but also by directly reducing estradiol secretion via an ovarian mechanism. On the other hand, it may be possible that CET acts as an inhibitor of both the pituitary and ovary whereas agonists may not reduce gonadotropin release but directly act in the ovary.
To assess these putative divergent effects of CET versus BUS on the pituitary, we performed a second experiment with the focus on expression of relevant target genes in the pituitary. Only CET induced lower pituitary LH-␤ gene expression that corresponded with lower LH serum levels. BUS stimulated LH and FSH levels along with elevated gene expression of the alpha-subunit and FSH-␤ and slightly, but not significantly, increased amounts of LH-␤-subunit mRNA. It should be emphasized that these observations were made 2 h after the last injection of the 10-d treatment.
Therapy of precocious puberty aims to prevent the action of untimely released endogenous GnRH by blocking the primary target, i.e. the pituitary, ideally causing a reduction of GnRH receptor gene expression and lower LH secretion because of "down-regulation" of the GnRH receptor. In our experiments with female peripubertal rats, only CET met both criteria, i.e. it inhibited GnRH receptor-mRNA levels in the pituitary and reduced gonadotropin levels in the serum. In a previous study with adult male rats it has been shown that CET decreased the number of GnRH receptor binding sites along with reduced GnRH receptor gene expression (35) . It appears that CET prevents the binding of endogenous GnRH to its receptor without appreciable intrinsic effect on LH biosynthesis and release.
Further support for the lack of intrinsic effects of CET comes from a clinical study on normal men. In this study, after an initial high loading dose of CET, a lower daily maintenance dose was sufficient for suppression of LH, FSH, and testoster- 472 one (9) . This reduction of the therapeutically efficient drug doses compared with the required continuation of regular injections of GnRH agonists to avoid reactivation of the gonadotropin and gonadal steroid hormone secretion may be advantageous in the use of CET versus agonists. It thus appears that GnRH antagonists may have two actions on the GnRH receptor: initially, and possibly most importantly, a competitive mechanism that prevents binding of endogenously released GnRH that is then followed by a down-regulation of pituitary GnRH receptors. This would explain the lower maintenance dose of the antagonists required for effective gonadotropin suppression.
This study shows that CET has only inhibiting effects on pituitary hormone secretion and gonadotropin subunit expression in peripubertal rats versus the stimulating as well as inhibiting effects observed for the GnRH agonists BUS and TRIP. Our data also suggest that CET affects pituitary LH release more specifically than BUS because of its parallel inhibition of transcription and secretion of LH. These more targeted effects coupled with CET's minimal side effects and lower maintenance dosage requirement would suggest that treatment of central precocious puberty is a potential clinical application for CET. RT of each animal sample was carried out with same amount of mutant cRNA. In CET-treated rats, LH-␤ was lower than in BUS or placebo group, whereas BUS-treated animals had a significantly higher FSH-␤ and alpha subunit expression, *p Ͻ 0.01 compared with controls.
INHIBITION OF PUBERTY BY GnRH ANALOGUES
